Valneva Overview

  • Founded
  • 1999

Founded
  • Status
  • Public

  • Employees
  • 628

Employees
  • Stock Symbol
  • VLA

Stock Symbol
  • Investments
  • 4

  • Share Price
  • $6.79

  • (As of Wednesday Closing)

Valneva General Information

Description

Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for travellers; one for the prevention of Japanese encephalitis (IXIARO) and the second (DUKORAL) for the prevention of cholera and diarrhoea. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, and third-party products; Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; and Technologies and services which relates to services and inventions at a commercialization stage. The group is based in France and operates internationally.

Contact Information

Website
www.valneva.com
Formerly Known As
Vivalis
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PAR
Primary Office
  • 6, Rue Alain Bombard
  • 44800 Saint-Herblain
  • France
+33 02 00 00 00 00

Valneva Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Valneva Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.79 $6.78 $4.81 - $20.61 $940M 138M 358K $0.91

Valneva Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 389,763 2,651,647 814,142 279,305
Revenue 571,418 411,540 125,756 141,269
EBITDA 103,378 (46,068) (51,163) 11,302
Net Income 79,451 (86,810) (73,402) (1,952)
Total Assets 686,137 925,423 552,457 296,535
Total Debt 158,853 129,815 129,701 95,457
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Valneva Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Valneva‘s full profile, request access.

Request a free trial

Valneva Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes two vaccines for trav
Biotechnology
Saint-Herblain, France
628 As of 2022
00000
00000000 00000

000000

g elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut en
0000 000000000
Tubingen, Germany
0000 As of 0000
00.000
00000000 00.000

000000

in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000000000000
Gaithersburg, MD
0000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Valneva Competitors (80)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CureVac Formerly VC-backed Tubingen, Germany 0000 00.000 00000000 00.000
0000000 Corporation Gaithersburg, MD 0000 00000 000000000 00000
0000000 Corporation Beijing, China 0000 00000 000000 - 000 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
0000000 0000000000 Corporation Emeryville, CA 000 00000 000000000 00000
You’re viewing 5 of 80 competitors. Get the full list »

Valneva Patents

Valneva Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3174666-A1 Improved methods of producing a lipidated protein Pending 09-Apr-2020 000000000
CA-3174599-A1 Improvements in vaccine formulations for medical use Pending 09-Apr-2020 000000000
AU-2021253605-A1 Inactivated sars-cov-2 virus vaccine Pending 06-Apr-2020 000000000
CA-3168784-A1 Inactivated sars-cov-2 virus vaccine Pending 06-Apr-2020 000000000
EP-3955959-A2 Inactivated sars-cov-2 virus vaccine Pending 06-Apr-2020 A61K39/12
To view Valneva’s complete patent history, request access »

Valneva Executive Team (15)

Name Title Board Seat Contact Info
Thomas Lingelbach Chief Executive Officer & Executive
Peter Buhler Chief Financial Officer, Finance & Executive
Vincent Dequenne Chief Operating Officer
Frederic Jacotot General Counsel, Legal & Executive
Juan Jaramillo MD Chief Medical Officer & Executive
You’re viewing 5 of 15 executive team members. Get the full list »

Valneva Board Members (14)

Name Representing Role Since
Alain Munoz Ph.D Self Scientific Advisory Board Member 000 0000
Anne-Marie Graffin Valneva Supervisory Board Member 000 0000
Anne-Marie Graffin Self Board Member 000 0000
Frederic Grimaud Valneva Chairman & Board Member 000 0000
James Sulat Self Board Member & Vice Chairman 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Valneva Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Valneva Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Valneva‘s full profile, request access.

Request a free trial

Valneva Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 00000 09-Feb-2015 0000000000 000.00 Biotechnology 000000 00
00000 0000000 11-Dec-2014 00000 0000 00.000 Biotechnology 000000 00
000000000 16-Dec-2012 000000 00 Biotechnology
Humalys 01-Jan-2010 Merger/Acquisition 000.00 Biotechnology
To view Valneva’s complete investments and acquisitions history, request access »

Valneva ESG

Risk Overview

Risk Rating

Updated January, 14, 2023

29.03 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 465

Rank

00.00

Percentile

To view Valneva’s complete esg history, request access »